DRG Epidemiology's coverage neuroblastoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of neuroblastoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's neuroblastoma forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with neuroblastoma per year?
- Of all people diagnosed with neuroblastoma, how many in each country are first line drug-treatable?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of neuroblastoma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts 6 neuroblastoma patient populations, as follows:
- Neuroblastoma diagnosed incident cases
- Diagnosed localized neuroblastoma
- Diagnosed regional neuroblastoma
- Diagnosed distant neuroblastoma
- Diagnosed 1st line drug-treatable neuroblastoma
Note: coverage may vary by country.
- Neuroblastoma - Epidemiology - Emerging Markets
Author(s): Nishant Kumar, MPH
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.
His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.